OncoMatch/Clinical Trials/NCT07759856
NK Cells Plus ICI for SCLC Maintenance
Is NCT07759856 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Allogeneic Natural Killer Cells and Immune Checkpoint Inhibitor for small cell lung cancer.
Treatment: Allogeneic Natural Killer Cells · Immune Checkpoint Inhibitor — This research study is designed for patients with extensive-stage small cell lung cancer (ES-SCLC) who have already received four cycles of standard chemotherapy, with at least two cycles combined with immunotherapy, and have achieved disease control (stable disease, partial response, or complete response) at their last efficacy evaluation. In this study, participants will be randomly assigned to one of two groups: Group A will receive standard immunotherapy plus 1 to 3 courses of allogeneic natural killer (NK) cell therapy. Each course consists of six NK cell infusions given over 28 days. Group B will receive standard immunotherapy alone. All participants will continue treatment until their disease progresses or they experience unacceptable side effects. The immunotherapy agents used in this study are those recommended by major international and national clinical guidelines for extensive-stage SCLC, including but not limited to durvalumab, atezolizumab, serplulimab, and adebrelimab. The purpose of this study is to evaluate whether adding NK cell therapy to standard immunotherapy can provide additional benefits for patients with extensive-stage SCLC who have responded well to initial treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage IV
metastatic or extensive-stage small cell lung cancer (SCLC) confirmed by histology or cytology
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy — first-line extensive-stage SCLC
followed by 4 cycles of platinum-based doublet-chemotherapy with at least 2 cycles of immune checkpoint inhibitor plus chemotherapy
Must have received: checkpoint inhibitor (durvalumab, atezolizumab, slulizumab, adbelimumab, toripalimab) — first-line extensive-stage SCLC
at least 2 cycles of immune checkpoint inhibitor plus chemotherapy. The checkpoint inhibitors used were those recommended by the NCCN, ESMO, and CSCO guidelines for extensivestage SCLC, including but not limited to: Duvalumab, atezolizumab, slulizumab, adbelimumab, toripalimab, etc.
Lab requirements
Blood counts
ANC≥1.5×10^9/L, HB≥70 g/L (blood transfusion allowed), PLT≥80×10^9/L
Kidney function
uric acid <500 μmol/L, serum creatinine <1.7 mg/dL, proteinuria ≤2+ or ≤2g/24h, glomerular filtration rate (GFR) ≥60 ml/min/1.73m2
Liver function
ALT≤3×ULN, AST≤3×ULN, TBIL≤2×ULN (patients with liver metastasis ALT≤5×ULN, AST≤5×ULN, TBIL≤2×ULN) Child-Pugh score ≤7
bone marrow function: ANC≥1.5×10^9/L, HB≥70 g/L (blood transfusion allowed), PLT≥80×10^9/L; Liver function: ALT≤3×ULN, AST≤3×ULN, TBIL≤2×ULN (patients with liver metastasis ALT≤5×ULN, AST≤5×ULN, TBIL≤2×ULN) Child-Pugh score ≤7; Renal function: uric acid <500 μmol/L, serum creatinine <1.7 mg/dL, proteinuria ≤2+ or ≤2g/24h, glomerular filtration rate (GFR) ≥60 ml/min/1.73m2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07759856 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received platinum-based chemotherapy and checkpoint inhibitor.
What disease stage is eligible?
Stage IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages